乌美溴铵维兰特罗(Umeclidinium Bromide/Vilanterol Trifenatate) - 药物靶点：M1 receptor x M2 receptor x M3 receptor x M4 receptor x M5 receptor x β2-adrenergic receptor_在研适应症：慢性阻塞性肺疾病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

GSK-573719/Vilanterol、LAMA/LABA、UMEC/VI

+ [14]

靶点

M1 receptor x M2 receptor x M3 receptor x M4 receptor x M5 receptor x β2-adrenergic receptor

作用方式

拮抗剂、激动剂

作用机制

M1 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M1拮抗剂)、M2 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M2拮抗剂)、M3 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M3拮抗剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

GlaxoSmithKline (Ireland) Ltd.GlaxoSmithKline Intellectual Property Development Ltd.Aerorx Therapeutics, Inc.

+ [1]

非在研机构

GSK Plc

最高研发阶段批准上市

首次获批日期

美国 (2013-12-18),

慢性阻塞性肺疾病

最高研发阶段(中国)批准上市

特殊审评优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C44H49Cl2NO7

InChIKeyKLOLZALDXGTNQE-JIDHJSLPSA-N

CAS号503070-58-4

查看全部结构式(2)

关联

43

项与乌美溴铵维兰特罗相关的临床试验

NCT06841640

/ Recruiting临床1/2期

Two-part, Single-dose, Dose-finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Bronchodilator Effects of AERO-007 Inhalation Solution Using a General Purpose Nebulizer in Healthy Volunteers and Subjects With COPD

This is a phase 1/phase 2a, single dose, crossover study conducted in two parts.
Part 1: Phase 1, open-label, 4-period crossover study in 8 healthy subjects to determine the optimal dose of AERO-001 and AERO-002, the active components of AERO-007 combo bronchodilator, using the systemic pharmacokinetic (PK) profile.
Part 2: Phase 2a, randomized, double-blind, placebo-controlled, 3-period crossover study in 16 subjects with COPD to determine the safety, tolerability, PK, and bronchodilator profile of AERO-007 inhalation solution administered via oral inhalation using a general-purpose nebulizer.

开始日期2025-01-15

申办/合作机构

Aerorx Therapeutics, Inc.

NCT06474039

/ Not yet recruiting临床3期IIT

The Efficacy of Fluticasone Furoate/Vilanterol/Umeclidinium Compared With Vilanterol/Umeclidinium in Reducing Air Trapping and Airway and Blood Cytokine Levels in COPD

This study aims to demonstrate the effects of triple therapy (ICS/LABA/LAMA) and dual bronchodilators (LAMA/LABA) on air trapping in the lungs' COPD patients and inflammatory mediators

开始日期2024-06-01

申办/合作机构

Mahidol University

NCT06571942

/ Recruiting临床4期IIT

Effect of the Inhaled Triple Therapies Over the Small Airway in Patients With Chronic Obstructive Pulmonary Disease or Chronic Bronchitis Without Obstruction Secondary to Biomass Exposure: Randomized Controlled Clinical Trial Phase IV

This phase IV randomized controlled clinical trial intend to compare the effect of three close standard inhaled triple therapies and one close standard inhaled double therapy on the small airway in patients with Chronic Obstructive Pulmonary Disease (COPD-B) and chronic bronchitis without obstruction (BCNO) exposed to wood smoke. The treatment phase duration is of 3 months. As primary outcome, the resistance change in post-bronchodilatator impulse oscilometry will me measure at 30 minutes, 2 hours, 4 hours, and 24 hours post first dose of the asigned medication, and then at 1 and 3 months of treatment. As secondary outcomes, change in respiratory symptoms and health related quality of life will be assess after 1 and 3 months of treatment.

开始日期2023-11-15

申办/合作机构

National Institute of Respiratory Diseases, Mexico

100 项与乌美溴铵维兰特罗相关的临床结果

登录后查看更多信息

100 项与乌美溴铵维兰特罗相关的转化医学

登录后查看更多信息

100 项与乌美溴铵维兰特罗相关的专利（医药）

登录后查看更多信息

159

项与乌美溴铵维兰特罗相关的文献（医药）

2025-03-01·Pulmonary Therapy

Retrospective Cohort Study of Elderly Users of Single- or Multiple-Inhaler Triple Therapy for the Treatment of Asthma in the USA

Article

作者: Laliberté, Francois ; Paczkowski, Rosirene ; Burrows, Emmeline ; Duh, Mei Sheng ; Mahendran, Malena ; Settipane, Russell A ; Germain, Guillaume ; Hilts, Annalise

INTRODUCTION:

Escalation to single- or multiple-inhaler triple therapy (SITT; MITT) is a recommended option for patients with asthma who remain uncontrolled by medium-dose inhaled corticosteroid/long-acting β₂-agonist; however, characterization of elderly users of triple therapy is limited. This real-world cohort study describes demographics and clinical characteristics of elderly patients with asthma with and without comorbid chronic obstructive pulmonary disease (COPD) who are new users of triple therapy, and asthma treatment patterns preceding triple therapy initiation.

METHODS:

This retrospective cohort study used administrative claims data from the Optum Clinformatics Data Mart database. Eligible patients were ≥ 65 years of age with asthma or with asthma and comorbid COPD who initiated either triple therapy with single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; 100/62.5/25 μg) or MITT between September 18, 2017 and September 30, 2020. Demographics, clinical characteristics, healthcare resource utilization, healthcare costs, and asthma treatment patterns were described in the 12-month period before triple therapy initiation (baseline period).

RESULTS:

In total, 15,557 patients were included. Among FF/UMEC/VI initiators with asthma (N = 635) mean age was 73.3 years and 66.6% were female. During the baseline period, > 75% of patients used controller therapy, > 92% used rescue medications, 27.9% experienced ≥ 1 asthma-related exacerbation, with mean annual exacerbation rate of 0.42, and mean all-cause healthcare costs were $23,407. Patients with asthma initiating MITT and patients with asthma and comorbid COPD initiating FF/UMEC/VI or MITT had similar characteristics, healthcare resource utilization, healthcare costs, and asthma treatment patterns to FF/UMEC/VI initiators with asthma.

CONCLUSIONS:

Triple therapy is often initiated following use of other asthma controller medications in real-world practice. Substantial rescue medication use and high disease and economic burden among this elderly patient population suggest that their asthma was not adequately controlled prior to triple therapy initiation. This retrospective study provides an early profile of elderly patients with asthma in the USA.

2025-02-01·ADVANCES IN THERAPY

Medicare Advantage Population in the United States: Outcomes of Patients with Asthma Treated with ICS/LABA Before and After Initiation with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)

Article

作者: Paczkowski, Rosirene ; Laliberté, François ; Schell, Robert C ; Baptist, Alan P ; Forero-Schwanhaeuser, Sergio ; Klimek, Jacob ; Moore, Alison ; Germain, Guillaume ; Noorduyn, Stephen G

INTRODUCTION:

The clinical benefits of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) have been demonstrated in clinical trials. There is limited evidence regarding the effectiveness and economic outcomes associated with FF/UMEC/VI use in US clinical practice. This real-world study assessed asthma-related exacerbations, healthcare resource utilization (HRU), and healthcare costs among a Medicare Advantage-insured population before and after initiation of FF/UMEC/VI in patients with asthma previously treated with an inhaled corticosteroid/long-acting β₂-agonist (ICS/LABA).

METHODS:

De-identified data were obtained from the Komodo Health database (01/01/2016-12/31/2023) for adults with asthma who received prior ICS/LABA treatment and had ≥ 12 months of continuous Medicare Advantage coverage both pre- and post-FF/UMEC/VI initiation (index date). Rates of asthma-related exacerbations and HRU were compared using rate ratios (RR) from Poisson regressions. Healthcare costs were calculated per patient per year (PPPY) and compared using mean cost differences from generalized linear models.

RESULTS:

In total, 2598 Medicare Advantage-insured patients who initiated FF/UMEC/VI for asthma were included. The mean ± SD age was 67.9 ± 12.3 years; 75.5% were female. The rate of overall asthma-related exacerbations was 31% lower in the post- versus pre-initiation period (RR 0.69; 95% CI 0.65, 0.73; p < 0.001) and included a 24% lower rate of inpatient/emergency department (IP/ED)-defined exacerbations (RR 0.76; 95% CI 0.68, 0.85; p < 0.001) and a 34% lower rate of systemic corticosteroid (SCS)-defined exacerbations (RR 0.66; 95% CI 0.61, 0.71; p < 0.001). Asthma-related ED visits (RR 0.69; 95% CI 0.60, 0.80; p < 0.001) and asthma-related outpatient (OP) visits (RR 0.77; 95% CI 0.71, 0.84; p < 0.001) were both lower, and the mean reduction in cost was $411 PPPY (95% CI $575, $248; p < 0.001), after FF/UMEC/VI initiation.

CONCLUSIONS:

Initiation of FF/UMEC/VI after ICS/LABA treatment among Medicare Advantage-insured patients with asthma was associated with reduced rates of asthma-related exacerbations, ED and OP visits, and healthcare costs, highlighting the benefits of therapy escalation among this patient population.

2025-02-01·EUROPEAN RESPIRATORY JOURNAL

ECG-based risk factors for adverse cardiopulmonary events and treatment outcomes in COPD

Article

作者: Halpin, David M G ; Criner, Gerard J. ; Wise, Robert A ; Criner, Gerard J ; Dransfield, Mark T. ; Halpin, David M.G. ; Wade, R. Chad ; Lipson, David A. ; Singh, Dave ; Dransfield, Mark T ; Lipson, David A ; Wade, R Chad ; Martinez, Fernando J ; Han, MeiLan K ; Martinez, Fernando J. ; Kalhan, Ravi ; Tombs, Lee ; Wise, Robert A. ; Han, MeiLan K.

Background:

COPD has high mortality, compounded by comorbid cardiovascular disease. We investigated two ECG markers, Cardiac Infarction Injury Score (CIIS) and P pulmonale, as prognostic tools for adverse cardiopulmonary events in COPD.

Methods:

This was apost hocanalysis of the IMPACT trial. Outcomes included odds (odds ratio, 95% confidence intervals) of adverse cardiopulmonary events stratified by CIIS threshold (<20versus≥20) and P pulmonale (baseline). Events included all-cause death, hospitalisation or death, cardiovascular adverse event of special interest, severe COPD exacerbations, and moderate/severe COPD exacerbations. We also assessed the effects of fluticasone furoate/umeclidinium/vilanterolversusfluticasone furoate/vilanterol or umeclidinium/vilanterol based on CIIS and P pulmonale.

Results:

We included 9448 patients. Patients with CIIS ≥20 (versusCIIS <20) had greater odds of all-cause death (OR 1.73, 95% CI 1.27–2.37, p<0.001), hospitalisation or death (OR 1.33, 95% CI 1.17–1.50, p<0.001), cardiovascular adverse event of special interest (OR 1.27, 95% CI 1.08–1.48, p<0.005), severe COPD exacerbations (OR 1.41, 95% CI 1.21–1.64, p<0.001) and moderate/severe COPD exacerbations (OR 1.25, 95% CI 1.13–1.40, p<0.001). Patients with P pulmonale (versuswithout) had greater odds of all-cause death (OR 2.25, 95% CI 1.54–3.29, p<0.001), hospitalisation or death (OR 1.51, 95% CI 1.28–1.79, p<0.001), severe COPD exacerbations (OR 2.00, 95% CI 1.65–2.41, p<0.001) and moderate/severe COPD exacerbations (OR 1.25, 95% CI 1.08–1.46, p<0.001). A combined model demonstrated that patients with CIIS ≥20 and P pulmonale had increased risk of all-cause death (OR 3.38, 95% CI 1.23–9.30, p=0.019), hospitalisation or death (OR 1.61, 95% CI 1.14–2.22, p=0.004) and rate of severe COPD exacerbations (OR 1.89, 95% CI 1.22–2.91, p=0.004) and moderate/severe COPD exacerbations (OR 1.25, 95% CI 1.00–1.56, p=0.046). The risk of all-cause death and cardiovascular adverse events of special interest was reduced with fluticasone furoate/umeclidinium/vilanterolversusumeclidinium/vilanterol in patients with CIIS ≥20, but not CIIS <20.

Conclusions:

These findings suggest the potential clinical relevance of CIIS and P pulmonale as risk indicators for adverse cardiopulmonary events in COPD.

80

项与乌美溴铵维兰特罗相关的新闻（医药）

2025-03-03

·正大天晴药业集团

月度盘点 | 正大天晴2月要闻回顾

过去的一个月正大天晴发生了哪些新鲜事让我们一起来回顾一下吧 #1 国产首创突破！妥洛特罗贴剂（德瑞妥）获批上市，守护全年龄段呼吸疾病患者健康 2月7日，北京泰德制药研发的妥洛特罗贴剂（商标名：德瑞妥）获得国家药品监督管理局颁发的上市批件，是首个获批上市的国产妥洛特罗贴剂。这款创新贴剂，通过透皮给药系统实现药剂缓释，即可在“晨降”高危时段持续舒张支气管，降低夜间发病风险。正大天晴将携手北京泰德制药保证该产品供应，守护全年龄段呼吸疾病患者健康。（点击此处跳转至原链接） #2 正大天晴国内率先完成等效性研究，乌美溴铵维兰特罗吸入粉雾剂上市申请获受理 2月9日，正大天晴开发的乌美溴铵维兰特罗吸入粉雾剂上市申请获CDE受理，适用于慢性阻塞性肺疾病（COPD）的长期维持治疗，有望为国内超1亿慢阻肺病患者提供新的治疗选择。正大天晴作为国内首家完成双支扩粉雾剂等效性研究的医药企业，此次申报进程的推进将进一步巩固公司在呼吸系统疾病治疗领域的领先地位。（点击此处跳转至原链接） #3 彭博《商业周刊》专访谢其润：只有创新才能在全球医药竞争中立足中国生物制药董事会主席谢其润获选“2024彭博《商业周刊》年度人物50”。2月14日，《商业周刊》发表了题为《中国生物制药董事会主席谢其润：只有创新才能在全球医药竞争中立足》的专访文章。（点击此处跳转至原链接） #4 纳入国家优化创新药临床试验审评试点项目，正大天晴1类新药研发提速 2月11日，正大天晴申报的1类创新药TQB2210临床试验申请获国家药监局药品审评中心（CDE）受理。作为公司首个纳入《优化创新药临床试验审评审批试点工作方案》的试点项目，TQB2210临床试验审评周期将缩短50%以上，从而有望更快惠及肿瘤患者。近年来，企业通过研发投入与政策借力，实现创新药管线的爆发式增长。（点击此处跳转至原链接） #5 安罗替尼“再挑战”研究入选2025 ESMO SRCC小型口头报告盐酸安罗替尼关于晚期软组织肉瘤（STS）的多中心回顾性研究，入选2025年欧洲肿瘤内科学会肉瘤及罕见肿瘤大会（ESMO SRCC）小型口头报告（Mini Oral）。该研究聚焦于安罗替尼“再挑战”既往治疗发生进展STS患者的疗效与安全性，将于3月20日至22日在瑞士卢加诺举行的大会上展示最新研究数据。（点击此处跳转至原链接） #6 南京市委书记周红波会见谢承润：支持打造百亿级链主企业共建生物医药创新发展高地 2月19日，南京市委书记周红波会见中国生物制药首席执行长、正大天晴董事长谢承润一行。（点击此处跳转至原链接） #7 《新华日报》头版头条文章点赞正大天晴 2月20日，《新华日报》头版头条发表文章《其命维新，稳步走好“第一方阵”》，对2024年江苏因地制宜发展新质生产力，“创新江苏”多项指标全国居首，进行了深度报道。其中，正大天晴聚焦国际前沿靶点，在肿瘤、肝病、呼吸等重点治疗领域创新药物研发成果斐然受到关注。（点击此处跳转至原链接） #8 当选上海生物医药商会副会长谢承润:以“创新”“国际化”为战略双翼构建全球化产业协同体系 2月22日，上海市工商联生物医药商会第一届一次会员会议暨生物医药发展大会举行。上海市副市长刘多、陈宇剑，市政协副主席、市工商联主席寿子琪，中国药学会理事长孙咸泽出席。当选副会长的中国生物制药首席执行长、正大天晴董事长谢承润受邀参加“创新与出海”圆桌会，表示将以“数字化赋能”与“生态链协同”推动创新突破与国际化布局，与行业伙伴携手推动中国医药从“跟随”到“引领”的跨越。（点击此处跳转至原链接） #9 正大天晴“靶免联合”新突破，肺巨细胞癌患者无进展生存期达30个月 1类创新药安罗替尼联合派安普利单抗治疗晚期肺巨细胞癌的罕见病例报道，在医学期刊《Frontiers in Oncology》上发表，成功帮助一名晚期肺巨细胞癌伴脑转移、PD-L1高表达和TP53突变患者实现无进展生存30个月，为罕见肺癌治疗提供了新的思路和希望。（点击此处跳转至原链接） #10 “天韵”破局！新研究为血液病合并脓毒症治疗提供关键证据当地时间2月23日至25日，一项关于多黏菌素E甲磺酸钠（商标名：天韵）治疗血液病合并脓毒症的研究在美国重症医学会年会（SCCM 2025）以口头报告的形式公布，为破解这一困局提供了关键证据。（点击此处跳转至原链接） #11 关注罕见病，让生命不因“罕见”而孤独全球3.5亿罕见病患者中，中国有近2000万患者在与命运抗争。正大天晴2款在研的重磅产品正致力于攻克《罕见病目录》中的治疗难题。《罕见病目录》之外，正大天晴还有4款1类新药，正在向发病率极低的国际罕见病种发起挑战。（点击此处跳转至原链接）注：以上内容根据本公众号发稿时间统计。声明：本文的著作权由原作者或本公司享有，未经授权，不得以转载、复制、摄制、改编、汇编等方式使用。文中出现的人物肖像，其肖像权归本人所有，未经授权，禁止使用。 ● 月度盘点 | 正大天晴12月要闻回顾 ● 月度盘点 | 正大天晴11月要闻回顾 ● 月度盘点 | 正大天晴10月要闻回顾

上市批准申请上市

2025-02-20

·正大天晴药业集团

南京市委书记周红波会见谢承润：支持打造百亿级链主企业共建生物医药创新发展高地

2月19日，南京市委书记周红波会见中国生物制药首席执行长、正大天晴董事长谢承润一行。双方围绕深化合作深入交流，一致表示，生物医药是关系国计民生和国家安全的战略性新兴产业，是培育发展新质生产力的重要方向。南京生物医药产业生态优、企业活力足、创新药品多，发展前景广阔。南京将大力支持正大天晴等企业增资扩产、创新研发、拓展市场，打造百亿级链主企业，依法保护企业合法权益，持续构建良好生态，推动产业集群发展，共同建设更具竞争力的生物医药创新发展高地。谢承润表示，正大天晴将立足南京、深耕南京，为南京生物医药产业壮大和经济高质量发展贡献力量。南京市领导黎辉、戴华杰，正大天晴副总裁陈辉参加。声明：本文的著作权由原作者或本公司享有，未经授权，不得以转载、复制、摄制、改编、汇编等方式使用。文中出现的人物肖像，其肖像权归本人所有，未经授权，禁止使用。内容来源：南京日报 ● 彭博《商业周刊》专访谢其润：只有创新才能在全球医药竞争中立足 ● 安罗替尼“再挑战”研究入选2025 ESMO SRCC小型口头报告 ● 纳入国家优化创新药临床试验审评试点项目，正大天晴1类新药研发提速 ● 正大天晴国内率先完成等效性研究，乌美溴铵维兰特罗吸入粉雾剂上市申请获受理

医药出海

2025-02-18

·正大天晴药业集团

安罗替尼“再挑战”研究入选2025 ESMO SRCC小型口头报告

正大天晴1类创新药在国际舞台再传捷报！盐酸安罗替尼关于晚期软组织肉瘤（STS）的多中心回顾性研究，入选2025年欧洲肿瘤内科学会肉瘤及罕见肿瘤大会（ESMO SRCC）小型口头报告（Mini Oral）。该研究聚焦于安罗替尼“再挑战”既往治疗发生进展STS患者的疗效与安全性，将于3月20日至22日在瑞士卢加诺举行的大会上展示最新研究数据。软组织肉瘤（STS）是一种起源于脂肪、肌肉、血管、神经等间叶组织的恶性肿瘤，它的发病率仅占所有恶性肿瘤的1%。近年来，以酪氨酸激酶抑制剂（TKIs）为代表的抗血管靶向药物的兴起，让晚期无法手术或不能耐受化疗的STS患者获得了更好的生存。然而，据研究发现，所有从TKIs中获益的STS患者最终均会面临耐药问题。对此类患者而言，通过更换不同联合方案而维持血管内皮生长因子受体（VEGFR）的持续抑制仍可能使其继续获益。盐酸安罗替尼是的一种新型的多靶点口服TKI，通过抑制VEGFR、PDGFR、FGFR及c-Kit等多个靶点，在抗肿瘤血管生成和抑制肿瘤细胞生长、复制及迁移等方面发挥重要作用。这项将于2025 ESMO SRCC亮相的小型口头报告，将公布以安罗替尼联合方案作为“再挑战”治疗方案，用于既往经安罗替尼治疗进展后的晚期STS患者的疗效与安全性研究数据。此次ESMO SRCC的学术认可，进一步提示了安罗替尼在经TKI治疗耐药后的晚期STS治疗选择中的独特价值。安罗替尼自2018年5月首次获批非小细胞肺癌适应症以来，已形成覆盖多个实体瘤的治疗版图，包括单药治疗软组织肉瘤、小细胞肺癌、甲状腺髓样癌、甲状腺分化癌，以及与贝莫苏拜单抗联合治疗广泛期小细胞肺癌、子宫内膜癌等。安罗替尼与贝莫苏拜单抗联合治疗肾细胞癌、与派安普利单抗联合治疗肝细胞癌等“联合疗法”已进入上市申请阶段。研究数据将在大会上正式公布，正大天晴药业集团公众号将持续关注并第一时间发布相关信息。声明： 1. 本新闻稿旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参阅，非广告用途。 2. 本公司不对任何药品和/或适应症作推荐。 3. 本新闻稿中涉及的信息仅供参考，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。 ● 彭博《商业周刊》专访谢其润：只有创新才能在全球医药竞争中立足 ● 纳入国家优化创新药临床试验审评试点项目，正大天晴1类新药研发提速 ● 正大天晴国内率先完成等效性研究，乌美溴铵维兰特罗吸入粉雾剂上市申请获受理 ● 国产首创突破！妥洛特罗贴剂（德瑞妥）获批上市，守护全年龄段呼吸疾病患者健康

临床研究申请上市

100 项与乌美溴铵维兰特罗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	乌美溴铵维兰特罗	R03AL03	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
慢性阻塞性肺疾病	美国	GlaxoSmithKline Intellectual Property Development Ltd.	2013-12-18

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
呼吸困难	临床3期	加拿大	GSK Plc	2012-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


study 214888 (ERS2022)	N/A	慢性阻塞性肺疾病维持	6,815	Umeclidinium/vilanterol (UMEC/VI)	夢憲鹹淵鑰衊廠膚範醖(觸範築願廠鬱簾襯願範) = 膚獵獵鏇觸鹽襯艱醖鑰網構顧範顧壓膚糧醖鏇 (遞網願願蓋齋繭憲鑰範 )	积极	2022-09-04
				Inhaled corticosteroid/long-acting β2-agonist (ICS/LABA)	夢憲鹹淵鑰衊廠膚範醖(觸範築願廠鬱簾襯願範) = 願齋鬱網網膚壓獵願顧網構顧範顧壓膚糧醖鏇 (遞網願願蓋齋繭憲鑰範 )
IMPACT (ERS2018)	临床3期	慢性阻塞性肺疾病	-	Fluticasone furoate/umeclidinium/vilanterol 100/62.5/25µg (FF/UMEC/VI)	餘醖築膚簾膚鹽憲觸鏇(廠醖醖願衊簾憲築廠夢) = 願夢襯蓋繭蓋艱觸鹽製遞壓蓋選積範襯鹹窪窪 (鹽觸遞鹹範鏇餘壓構繭 ) 更多	积极	2018-09-15
				Fluticasone furoate/vilanterol 100/25µg (FF/VI)	餘醖築膚簾膚鹽憲觸鏇(廠醖醖願衊簾憲築廠夢) = 製鹹網選鏇製顧壓窪膚遞壓蓋選積範襯鹹窪窪 (鹽觸遞鹹範鏇餘壓構繭 ) 更多
ERS2018	N/A	慢性阻塞性肺疾病	40	LABA/LAMA therapy (indacaterol /glycopyrronium 110/50mg once-daily)	憲蓋鬱鏇鏇憲選廠膚繭(餘窪繭壓齋鏇蓋糧顧窪) = 範衊鬱壓選製衊遞構選願鹽鹽淵鑰鬱鹹積憲憲 (範繭範簾獵積廠簾膚觸 )	积极	2018-09-15
NCT02799784 (204990, CTgov)	临床4期	慢性阻塞性肺疾病	236	Vilanterol+Umeclidinium (Umeclidinium/Vilanterol 62.5/25 mcg)	獵蓋積築獵襯鹽淵顧鑰(獵鹹築製膚簾窪憲齋膚) = 壓積積淵糧範願築壓簾鹽鑰構餘遞艱憲範齋蓋 (遞積獵構網鏇鹹製糧鏇, 0.0131) 更多	-	2018-07-02
				Tiotropium+Olodaterol (Tiotropium/Olodaterol 5/5 mcg)	獵蓋積築獵襯鹽淵顧鑰(獵鹹築製膚簾窪憲齋膚) = 遞鏇鹹築蓋獵築衊構壓鹽鑰構餘遞艱憲範齋蓋 (遞積獵構網鏇鹹製糧鏇, 0.0135) 更多
NCT02487446 \| NCT02487498 (Pubmed \| Lung)	临床3期	慢性阻塞性肺疾病	-	Indacaterol Maleate/Glycopyrronium Bromide	遞築繭觸選鹽鹹艱遞觸(艱顧鬱壓構憲鑰簾蓋窪) = 醖網願願夢遞夢簾壓襯範鹽構積範選衊齋醖構 (鏇糧築鹹顧鑰齋獵糧壓 )	-	2017-12-01
				Umeclidinium Bromide/Vilanterol	遞築繭觸選鹽鹹艱遞觸(艱顧鬱壓構憲鑰簾蓋窪) = 積憲顧鬱鏇遞淵醖構築範鹽構積範選衊齋醖構 (鏇糧築鹹顧鑰齋獵糧壓 )
NCT02799784 (Pubmed \| Adv Ther)	临床4期	慢性阻塞性肺疾病	236	Umeclidinium/Vilanterol	積夢鹽選窪構簾憲顧淵(鹽網積製鬱選鏇餘觸窪) = 獵鏇觸遞鏇艱鹹構顧鹽觸憲鹽選鏇觸範築夢製 (製鑰鬱願願鬱憲觸齋顧 )	-	2017-11-01
				Tiotropium/Olodaterol	積夢鹽選窪構簾憲顧淵(鹽網積製鬱選鏇餘觸窪) = 範艱淵廠蓋襯淵鏇構網觸憲鹽選鏇觸範築夢製 (製鑰鬱願願鬱憲觸齋顧 )
ERS2017	N/A	慢性阻塞性肺疾病	14	Umeclidinium/vilanterol 125/25μg	獵鹽糧遞鑰鏇衊構壓夢(壓膚遞艱襯願構淵顧鬱) = 淵憲糧遞選膚鹽衊齋積願鏇顧餘範鹽淵蓋齋獵 (窪窪齋鏇醖網範鬱餘簾, 0.15)	-	2017-09-01
NCT02275052 (CTgov)	临床4期	慢性阻塞性肺疾病	198	Placebo DPI+Albuterol/salbutamol MDI	鏇糧淵繭積艱遞醖壓範(網顧餘鏇膚淵構餘醖鏇) = 觸糧簾選簾鏇鹽鏇糧構顧獵鏇繭觸鬱齋憲積獵 (艱窪鹹壓觸積鹽鏇築構, 9.680) 更多	-	2017-06-06
NCT01899742 (Pubmed \| Int J Chron Obstruct Pulmon Dis) 人工标引	临床3期	慢性阻塞性肺疾病	494	Umeclidinium/vilanterol	夢築艱餘獵選範醖糧遞(繭淵衊製積構願鬱遞淵): difference = 88 (95% CI, 45 ~ 131), P-Value = <0.001 更多	优效	2017-02-24
				tiotropium
NCT01316900 \| NCT01316913 \| NCT01777334 (ZEP117115, Pubmed \| Adv Ther)	临床3期	慢性阻塞性肺疾病维持	1,747	Umeclidinium/Vilanterol 62.5/25 mcg/day	願廠醖鏇廠襯蓋遞網顧(鏇醖糧壓鹽餘壓窪憲憲) = 製顧襯襯艱觸廠憲餘願膚鹽獵選鑰遞積築簾範 (願衊衊選簾鹹夢製齋醖 )	-	2017-01-01
				Tiotropium 18 mcg/day	願廠醖鏇廠襯蓋遞網顧(鏇醖糧壓鹽餘壓窪憲憲) = 鬱範廠鏇築鑰觸製觸齋膚鹽獵選鑰遞積築簾範 (願衊衊選簾鹹夢製齋醖 )